• Events
    • EURETINA 2022 Hamburg
      • Registration Information
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Hotel Bookings
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
Menu
  • Events
    • EURETINA 2022 Hamburg
      • Registration Information
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Hotel Bookings
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login
  • February 19, 2017
  • Author: EURETINA Brief

Phase IIa trial recruits first patient for novel therapy directed towards treatment of Stargardt’s disease.

A Phase IIa human study, sponsored by Acucela Inc., based in Seattle, Washington, has announced the recruitment of its first patient to evaluate emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease. The experimental small molecule treatment, a visual cycle modulator, will be tested in a multicenter, randomized, blinded study to investigate the pharmacodynamics, safety and tolerability of emixustat in Stargardt’s patients that meet the designated inclusion criteria. An estimated 30 subjects will be enrolled at clinical sites in the United States and will be randomly assigned in a 1:1:1 ratio of emixustat 2.5 mg, emixustat 5 mg, and emixustat 10 mg.  The protocol involves patients taking the study drug orally once daily for one month.

 

The rationale behind the mode of action of the drug is understood to rest on the principle of reducing the impact of certain stressors in the retina, including light, oxygen tension and accumulation of toxic retinoid by-products. In particular, independent research in animal models suggests that reduction of visual chromophore biosynthesis in the visual cycle could potentially prevent retinal pathology caused by stressors such as light, retinoid by-products, and oxygen. More recent clinical studies, addressing safety, tolerability, and pharmacodynamics of emixustat, found that the treatment suppressed rod photoreceptor sensitivity in a dose-dependent and reversible manner. In a previous study in an allied retinal pathology, the majority of systemic adverse events were not considered treatment related, many of which were understood to have resolved on study or within 7 to 14 days after study drug cessation.

 

Stargardt disease is classified as a rare genetically inherited disorder affecting the retina of young patients often leading to slow progression of vision loss. Often referred to as juvenile macular degeneration, the disorder affects approximately 1 in 10,000 individuals worldwide, in which the most common genetic lesion is in the ABCA4 gene. The disease affects < 40,000 patients in the United States. where it is designated as an orphan disease. Previously, the FDA granted orphan drug designation to emixustat for the treatment of Stargardt disease. The emuxistat treatment represents an oral non-retinoid, small molecule inhibitor of RPE65 and previous animal studies have demonstrated that emixustat could inhibit RPE65 in a dose-dependent, reversible manner. Commenting on the clinical trial recruitment milestone, Dr. Hendrik Scholl, University Hospital in Basel Switzerland stated, “This is an important therapeutic development for patients with Stargardt Disease. Emixustat addresses a well-understood mechanism that leads to toxic accumulation of material underneath the retina linked to visual loss in Stargardt disease and therefore is a promising compound for this debilitating disease.”

PrevPrevious
NextNext

You might also like

World Retina Day: Taiwan Retinal Society – High myopia: from prevention to treatment

Read More

Subspecialty Session: Genetics I: Genetics of Inherited Retinal Dystrophies

Read More

Instructional Course: Proliferative vitreoretinopathy, surgical management and improved techniques

Read More

Meet the Keynote Speakers

Euretina Lecture with Sobha Sivaprasad
Opthalmologica Lecture with Enrico Borrelli
Ophthalmologica Lecture with Enrico Borrelli
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Gisbert Richard Lecture with Catherine Creuzot-Garcher
Kreissig Award Lecture with Hiroko Terasaki
Kreissig Award Lecture with Hiroko Terasaki

Secretariat Address
European Society of Retina Specialists
Ground Floor, The Apex Building 
Blackthorn Road
Sandyford Business Park
Co Dublin, D18 H6K2

Phone:+353 1 2100092
Email: [email protected]

EURETINA 2022 Hamburg

Opportunities

Memberships

Forum

About

Privacy Policy

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2022 All rights reserved

  • Events
    • EURETINA 2022 Hamburg
      • Registration Information
      • Main Programme
      • Satellite Symposia
      • Exhibitors
      • Hotel Bookings
      • Abstract Viewer
    • Future Meetings
    • Upcoming Digital Events
    • EURETINA 2021 Virtual
      • 2021 Virtual Sessions On-Demand (Members Only)
      • Programme
      • Satellite Symposia
      • Sponsors
  • Free Resources
    • Webinars
    • Podcasts
    • 2021 Virtual Session Abstracts
    • EURETINA Guidelines
    • EURETINA Brief
    • IME ePlatform
  • Membership
  • About
    • EURETINA Board
    • Subspecialty Sections
    • Bye-laws
  • Opportunities
    • Mentorship Programme 2022/23
    • RMCR grant programme
    • Observership Grant Programme
    • Women in Retina
    • YOURS
    • CME Credits
  • Member Login